{"id":"avastin-in-combination-with-roferon-a","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Avastin works by binding to VEGF, preventing its interaction with its receptor and thus inhibiting the formation of new blood vessels that tumors need to grow. Roferon-A, on the other hand, stimulates the immune system to recognize and attack cancer cells, and also has direct antiproliferative effects on tumor cells.","oneSentence":"Avastin (bevacizumab) inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF), while Roferon-A (interferon alfa-2a) modulates the immune response and has antiproliferative effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:41.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT02174172","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-18","conditions":"Solid Cancers","enrollment":158},{"nctId":"NCT01731158","phase":"PHASE2","title":"Sequential Therapy in Metastatic Renal Cell Carinoma","status":"COMPLETED","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2012-10","conditions":"Metastatic Renal Cell Carcinoma","enrollment":22},{"nctId":"NCT02627144","phase":"","title":"Bevacizumab in Metastatic Renal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Renal Cell Cancer","enrollment":365},{"nctId":"NCT00796757","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12","conditions":"Renal Cell Cancer","enrollment":146},{"nctId":"NCT00520403","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09","conditions":"Renal Cell Cancer","enrollment":25},{"nctId":"NCT00619268","phase":"PHASE2","title":"Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2008-02","conditions":"Metastatic Renal Cell Carcinoma","enrollment":160},{"nctId":"NCT00308607","phase":"PHASE2","title":"Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma","status":"COMPLETED","sponsor":"University of Turku","startDate":"2005-08","conditions":"Metastatic Melanoma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bevacizumab in combination with Interfereon-alfa"],"phase":"phase_2","status":"active","brandName":"Avastin in combination with Roferon-A","genericName":"Avastin in combination with Roferon-A","companyName":"Central European Society for Anticancer Drug Research","companyId":"central-european-society-for-anticancer-drug-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avastin (bevacizumab) inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF), while Roferon-A (interferon alfa-2a) modulates the immune response and has antiproliferative effects. Used for Metastatic colorectal cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}